Company Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.
It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.
Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,204 |
| CEO | Jan G.J. de Winkel |
Contact Details
Address: Carl Jacobsens Vej 30, Valby Copenhagen, 2500 Denmark | |
| Phone | 45 70 20 27 28 |
| Website | genmab.com |
Stock Details
| Ticker Symbol | GMAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| CIK Code | 0001434265 |
| CUSIP Number | 372303206 |
| ISIN Number | US3723032062 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President and Chief Executive Officer |
| Anthony Pagano | Executive Vice President and Chief Financial Officer |
| Anthony Mancini | Executive Vice President and Chief Operating Officer |
| Birgitte Stephensen M.Sc. | Executive Vice President and Chief Legal Officer |
| Christopher Cozic | Executive Vice President and Chief People Officer |
| Dr. Martine J. van Vugt Ph.D. | Executive Vice President and Chief Strategy Officer |
| Martin Schultz | Senior Director of Clinical Operations and Non-Independent Director |
| Dr. Judith V. Klimovsky M.D. | Executive Vice President and Chief Development Officer |
| Dr. Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
| Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials and Non-Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2024 | 6-K | Report of foreign issuer |
| Oct 4, 2024 | 6-K | Report of foreign issuer |
| Oct 1, 2024 | 6-K | Report of foreign issuer |
| Sep 26, 2024 | 6-K | Report of foreign issuer |
| Sep 11, 2024 | 6-K | Report of foreign issuer |
| Sep 10, 2024 | 6-K | Report of foreign issuer |
| Aug 21, 2024 | 6-K | Report of foreign issuer |
| Aug 14, 2024 | 6-K | Report of foreign issuer |
| Aug 13, 2024 | 6-K | Report of foreign issuer |
| Aug 8, 2024 | 6-K | Report of foreign issuer |